CTOR Overview

Citius Oncology, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapies. The Company’s lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. It is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the diphtheria toxin (DT) fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death.

Wall Street analysts forecast CTOR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTOR is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Citius Oncology Inc revenue for the last quarter amounts to 1.67M USD, decreased

Citius Oncology Inc. EPS for the last quarter amounts to -0.27 USD, increased 145.45

Citius Oncology Inc (CTOR) has 0 emplpoyees as of May 31 2026.

Today CTOR has the market capitalization of 74.20M USD.